21:21 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Alidornase alfa: Interim Ph II data

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led to a 4.1...
01:45 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Completed Ph II enrollment

Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX),...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Phase II started

Protalix began an open-label, Israeli Phase II trial to evaluate 2.5 mg inhaled AIR DNase once daily for 28 days in 15 patients switching over from Pulmozyme dornase alfa. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel...
07:00 , Apr 27, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/24 clsAerie Pharmaceuticals Inc. (NASDAQ:AERI)CanaccordCorey DavisDowngradeHold (from buy)-62%$12.87 NeedhamSerge BelangerDowngradeHold (from buy)RBC Capital MarketsAdnan ButtPrice targetDavis also lowered his target to $12 from $40 after Aerie reported that...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Protalix preclinical data

Protalix said PRX-110 showed improved enzyme kinetics, less sensitivity to inhibition by actin and improved ex vivo efficacy in sputum from CF patients vs. Pulmozyme dornase alfa. The company plans to submit an...